Two-hour analysis of a biopsy
Technion Professor Daphne Weihs has developed a fast test to analyze cancer cells. Biopsies are placed into a special gel and measured. Two hours later the extent that the cells have embedded denotes whether they are benign, non-metastatic or metastatic (potential or actual).
Sharing stuff that works
An Israeli startup has launched an online platform where people suffering from chronic diseases can share information to learn which treatments work best for their specific condition, based on the experience of their peers. The crowdsourcing site is appropriately called StuffThatWorks.
(personal survey for specific conditions)
Sleep and Dream
Professor Peretz Lavie (ex-President of Israel’s Technion Institute) founded the Technion Sleep Medicine Center and authored several books on sleep disorders. Thanks to Technion UK, he is giving a free (donations welcome) webinar on Weds 5th Aug at 6pm UK time – 1pm EST. Register below to view live.
So how is your health?
Another exciting webinar from Technion UK featuring Technion Professor Shai Shen-Orr (founder of CytoReason) one of the leading Israeli researchers into the mysteries of the immune system. Also featured is Professor Ester Sager who is developing biosensors to diagnose diseases within minutes.
US approval for AI mammography
Israel’s Zebra Medical Vision (reported previously) that uses artificial intelligence technology to help read medical scans, has received US FDA clearance for use of its algorithm to read mammograms. It already received European (CE) approval for its “HealthMammo” solution.
You’ve got Covid – is that bad news?
Two recent Jewish immigrants to Israel from France have developed an algorithm named PhysioZoo. Using data from a pulse oximeter (that measures oxygen in blood) the algorithm can determine if a Covid-19 patient is going to develop pneumonia long before symptoms appear.
Vitamin D impacts Covid-19 infection and severity
Scientists at Israel’s Bar-Ilan University have identified low plasma vitamin D level to be an independent risk factor for COVID-19 infection and hospitalization. They studied 782 Israeli COVID-19 positive patients and 7,807 COVID-19 negative patients.
Pre-clinical success for Covid-19 ARDS treatment
Israel’s BrainStorm (reported previously) reported promising results of pre-clinical trials for its Nurown treatment for Acute Respiratory Distress Syndrome (ARDS) brought about by Covid-19. The NurOwn cells reduced the cytokine storm and lung damage.
Bubbles plus ultrasound kills cancer
Tel Aviv University researchers have developed an innovative cancer treatment. They shoot microbubbles at cancer cells and then blow them up using ultrasound. This destroys 80% of the cancer cells and a simultaneous “trojan horse” immune system gene therapy kills the remaining 20%.
The 3rd most Covid-19 solutions
Cross-border investment specialists Cukierman & Co state that Israel has the most Covid-19 solutions, after the USA and China. Some 180 of Israel’s 1,600 life sciences companies are either fully or partially dedicated to coronavirus. Israel is also a top global pioneer in personalized medicine.